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Sunday, February 26, 2012 61ascreening methods, considers the protein conformation change upon binding by
using two different protein conformations and also takes into account the sol-
vation effect by including conserved water molecules in the active site. The top
ranked molecules from each pharmacophore hypothesis are further analyzed
according to their interactions with AKT-2 and the ultimate docking results
from Glide are compared with previously identified inhibitors based on struc-
ture and chemistry.
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Glioblastoma multiforme (GBM) is a very aggressive brain cancer in humans.
Even with improvements in surgical, radiation, and chemotherapy treatments,
current prognosis is bleak, with only a 14-month median survival time. LYN,
an important kinase involved in cell regulation, is often overexpressed in
GBM. This work addresses computational design of druglike small molecules
that could potentially inhibit LYN and thus hinder GBM progression. New pu-
tative LYN inhibitors were obtained by atomic substitutions and structural
alterations of bafetinib, a small molecule previously found to bind LYN. Drug-
like properties and toxicities of the designed molecules were evaluated using
the Osiris Property Explorer program. Molecules with no implied toxicities
and most favorable druglike properties were used for docking studies in the
ArgusLab program. Designed molecules that made the most stable docking
configurations with LYN, but no stable configurations with other kinases,
were identified as LYN-specific. Binding energies of the stable complexes
formed by these molecules and LYN were calculated. Possible utilization of
the designed molecules in drug research against GBM is discussed.
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As part of our effort to understand the determinants of drug binding to the Abl
tyrosine kinase, we determined the crystal structure of the Abl kinase domain
bound to a derivative of the PP1 nucleoside analog. Just as the cancer drug im-
atinib selectively inhibits the tyrosine kinase activity of c-Abl, c-Kit, and the
PDGF receptor, but is a poor inhibitor of the closely related Src kinases (1),
PP1 is a selective inhibitor of the Src family (2), c-Kit (3), and PDGFR kinases
but not of Abl tyrosine kinase activity (3, 4). In fact, PP1 is 1000X less effective
at inhibiting Abl and Bcr-Abl kinases than at inhibiting the Src kinases (3, 4).
We rationally designed a derivative of the PP1 compound to introduce hydro-
gen bonding between it and a strictly conserved lysine residue that coordinates
the alpha and beta phosphate groups of ATP in protein kinases (5). By expand-
ing the interactions between the inhibitor and Abl kinase, we sought to make
the PP1 derivative, AB129, less selective. Our crystal structure of the Abl ki-
nase domain bound to the AB129 inhibitor shows three important features.
First, the compound binds to the kinase domain in the active conformation: al-
pha C helix is rotated inward facilitating a salt bridge between Lys271 and
Glu286 and the conserved Asp-Phe-Gly (DFG) motif is oriented Asp-In. In
contrast, the structure of PP1 bound to the Src family kinase Hck is in the in-
active conformation (6). Second, the strictly conserved Glu286 residue, not
Lys271, hydrogen bonds to the hydroxyl group of AB129. Third, the conforma-
tion of the phosphate binding loop (P-loop) is extended. We provide kinetic and
calorimetric data to support our rationale for the observed conformational
changes.
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The uncontrolled kinase activity of the oncogenic protein Bcr-Abl is a hall-
mark of Chronic myelogenous leukemia (CML). Although the drug imtanib
is highly effective at shutting down aberrant Abl kinase activity, some
CML patients harbor additional mutations in their bcr-abl gene that renders
their gene product, the Bcr-Abl protein, resistant to this drug. Since secondgeneration Abl kinase inhibitors such as dasatinib are effective only against
particular resistant mutant proteins, new targeted agents are needed to combat
drug resistance. Two combi-inhibitors ZRF1 and ZRF2, which block Bcr-Abl
activity and damage DNA in the cell, have been shown to be more potent than
imatinib in cellular assays. Since both ZRF1 is hydrolyzed in the cell to ZRF0,
an imatinib analog in which only the mono-substituted benzamide piperazinyl
moiety is replaced with bi-substituted amino and trifluoromethyl groups, we
wondered why these two changes had such a profound effect on the potency
of the drug. To determine whether ZRF1/2’s increased potency was due to the
DNA damaging agent attached to the parent compounds, we sought to co-
crystallize the Abl kinase domain with these two inhibitors at room tempera-
ture and 4C using commercially available sparse-matrix screens. We
screened over 400 crystallization conditions, with Abl and ZRF1, ZRF2, or
dasatinib inhibitors but were unable to obtain crystals of either the Abl-
ZRF1 or Abl-ZRF2 drug complex. Protein crystals in wells containing the
Abl kinase domain and dasatinib, however, were evident in every tray. Since
ZRF1 and ZRF2 are hydrolyzed in the cell, future co-crystallization studies of
Abl and its mutant proteins will employ the hydrolyzed inhibitor analogs as
the ligand.
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The large and growing body of experimental data on biomolecular binding is of
enormous value in developing a deeper understanding of molecular biology, in
developing new therapeutics, and in various molecular design applications.
However, most of these data are found only in the published literature and
are therefore difficult to access and use. BindingDB is a public web-
accessible database of measured binding affinities for various molecular types.
The BindingDB allows queries based upon a range of criteria, including chem-
ical similarity or substructure, sequence homology, numerical criteria and reac-
tant names. The data specification includes significant experimental detail. The
time and expense required to extracting data from the literature, for this and
many other databases, highlight the importance of moving toward machine-
readable components of publications.
311-Pos Board B97
GALAXYDock: Docking Ligands to Receptor Proteins with Selected Flex-
ible Side-Chains
Woong-Hee Shin, Chaok Seok.
Seoul National University, Seoul, Korea, Republic of.
Protein-ligand docking techniques are one of the essential tools for structure-
based drug design. Although conformational changes of protein receptor fre-
quently occur in the binding process, a large fraction of contemporary docking
programs ignore receptor flexibility. Consideration of protein flexibility effi-
ciently and accurately in docking studies is challenging due to difficulties in
finding accurate scoring function and in sampling conformations efficiently.
Previously we developed a docking program called LigDockCSA which incor-
porates LigDock scoring function that combines AutoDock3 and PLP scoring
function and conformational space annealing (CSA) as a sampling method.
However, the program treats protein rigid. Here, we present GALAXYDock,
an extension of LigDockCSA that accounts flexibility of pre-selected side-
chains of receptor protein in the binding site. To test the performance of the
new docking method, 3 sets of protein-ligand complexes that share similar
backbone structures but have different side chain conformations were selected
as test sets: HIV-PR, LXRb and cAPK. The cross-docking results show that the
accuracy of binding pose prediction is increased about 20% when compared
with our previous rigid-receptor results.
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The study of the binding and effects of polyaromatic hydrocarbons (PAH) to
proteins remains one of the fundamental aspects of research in biophysics.
Among other processes, ligand binding can regulate the function of proteins in-
cluding inhibiting their action. Binding to small ligands remains a very im-
portant aspect in the study of the function of many proteins. We studied
a new class of 3,9-substituted perylene derivatives designed to optimize
